POLO: What the Pancreatic Cancer Trial Found

3,315 screened, 154 enrolled

That ratio is the first thing to understand about POLO. The trial screened 3,315 people with metastatic pancreatic cancer to find 154 who fit.

The requirement was an inherited change in the BRCA1 or BRCA2 gene, plus disease that had not worsened during first-line chemotherapy containing a platinum drug. Very few people meet both. The 154 who did were assigned 3 to 2: 92 to olaparib, 62 to placebo.

What the drug does

Olaparib is a PARP inhibitor. PARP stands for poly ADP-ribose polymerase, an enzyme that helps cells repair damage to their DNA.

Cells have more than one repair system. BRCA1 and BRCA2 run one of them. A person born with a faulty copy of either gene has tumors that lean heavily on the PARP route instead. Block PARP, and those cells lose their remaining way to fix DNA breaks, and they die. Healthy cells still have both systems and cope.

This is targeted therapy in its clearest form: a drug that only makes sense because of a specific inherited gene change. Our page on targeted therapy covers the wider idea.

What maintenance means

POLO did not test olaparib as the main treatment. Everyone had already had platinum-based chemotherapy and had not gotten worse on it.

Maintenance therapy is what comes after that, aimed at holding the line rather than shrinking the tumor further. This is why the question the trial asked was about time without progression, not about tumor response.

The result

Median progression-free survival was 7.4 months with olaparib against 3.8 months with placebo. The hazard ratio was 0.53, with a 95 percent confidence interval of 0.35 to 0.82, and p equal to 0.004.

Progression-free survival means time until the cancer grows or the person dies, whichever comes first. Here it was assessed by independent reviewers who did not know which treatment anyone had received.

That is roughly three and a half extra months before the disease moved again, in a cancer where such gains are rare.

What it did not show

Overall survival did not differ. At an interim analysis with 46 percent data maturity, median overall survival was 18.9 months with olaparib against 18.1 months with placebo. The hazard ratio was 0.91, and p was 0.68.

Quality of life did not differ either. The between-group difference on a 100-point scale was minus 2.47 points, which is not a meaningful gap.

Grade 3 or higher adverse events occurred in 40 percent of the olaparib group against 23 percent of the placebo group, a difference of 16 percentage points. Five percent of the olaparib group and 2 percent of the placebo group stopped treatment because of a side effect.

So: more time before progression, more serious side effects, no measured difference in how long people lived or how they felt. All three of those are the result. Our explainer on clinical trial phases sets out why a phase 3 trial can be positive on one endpoint and neutral on another.

Why the BRCA part matters beyond this drug

An inherited BRCA change is not only about treatment. It is inherited, which means relatives may carry it too.

That is why genetic testing in pancreatic cancer has become routine rather than exceptional. It can open a treatment option, and it can identify family members who may want testing and earlier surveillance for cancers linked to these genes.

Pancreatic cancer, in numbers

SEER records five-year relative survival for pancreatic cancer at 13.7 percent for people diagnosed from 2016 to 2022. By extent it is 43.6 percent for local disease, 17.0 percent for regional disease, and 3.4 percent for distant disease, which is how 51 percent of cases are found. Only 15 percent are still local at diagnosis.

Those are group averages and describe no individual. They also explain why an extra 3.6 months before progression counted as news.

When to raise pancreatic concerns

There is no screening test for pancreatic cancer for people at average risk. Symptoms are the entry point, and they are vague until they are not.

NCI lists these signs of pancreatic cancer: jaundice, meaning yellowing of the skin and whites of the eyes, light-colored stools, dark urine, pain in the upper or middle abdomen and back, weight loss for no known reason, loss of appetite, and feeling very tired. Jaundice with pale stools and dark urine is the combination to act on the same week.

If you have a strong family history of pancreatic, breast, ovarian, or prostate cancer, ask specifically about genetic counseling. Our overview of pancreatic cancer covers what surveillance is available to people at higher inherited risk.

What this trial cannot tell you

• POLO enrolled only people with an inherited BRCA1 or BRCA2 change and no progression on platinum chemotherapy. It says nothing about anyone else.
• Progression-free survival is a real measure, and it is not the same as living longer. Here, overall survival did not differ.
• The overall survival figure came from an interim analysis at 46 percent maturity. Interim results can shift.
• Serious side effects were substantially more common with the drug. That has to sit alongside the benefit, not below it.

Sources

• Golan T, et al., N Engl J Med 2019 — POLO abstract via NCBI E-utilities
• ClinicalTrials.gov API v2 record for NCT02184195
• NCI: Pancreatic Cancer Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Pancreatic Cancer

How this page was made

An AI-assisted editorial system helped prepare this page. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown. Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.